Novo Nordisk blocked from pharmaceutical industry group membership for two years over promotional drug campaign
The Association of the British Pharmaceutical Industry has suspended the company where the trade body’s former president is a senior manager from its membership due to “serious” code of conduct breaches.
Novo Nordisk, a Danish multinational pharmaceutical company, has been suspended for two years after an investigation found the company had breached the ABPI code in the course of sponsoring courses promoting its weight loss drug. The suspension includes the removal of the company from all ABPI groups, including its board, and access to any ABPI information and briefing.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.